Allink Biotherapeutics

Venture-backed company · Series A
Rounds on record
1
Latest round
Dec 16, 2025
Series A
Latest round size
$47.0M
More
Ask DFX about thisView relationshipsFinancing historyInvestorsOwnership and outcomes
As of · the latest observation of this company; each round carries its own date

4 additional investors

Every relationship, signal and contact on this record, with the source on each.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

What matters now

  1. $47M
    announced

    Announced a Series A ($47M round) on 16 Dec 2025.

    A company that just raised has fresh capital, a new board and new vendors to choose.

    FactPress release wires (PR Newswire, GlobeNewswire)For Investors, lenders, service providersFinancing history →
  2. 7 investors
    named

    7 investors on record; Legend Capital led a round.

    The investors already on the cap table shape who leads the next round.

    Factfunding announcements, portfolio pages and Form DFor Investors, foundersInvestors →
Drawing the relationship network…

Facts

Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$47.0Msum of rounds with a disclosed amount only
Named investors
7

Financing history

1 round
  1. Dec 16, 2025
    Series A · $47.0M (disclosed)
    YuanBio Venture Capital (participant)Lapam Capital (participant)Runzhang Venture Capital (participant)Legend Capital (lead) via Tan HongMeituan Long-Z Investment (lead) via Xuejing GuoVesey Ventures LP (lead)
    Fact Press release · “Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development”

Investors on record

7 edges

Ownership and outcomes

none on record
Outcome stated by investors

Listed on 1 firm portfolio page; none states an outcome (acquired, public, exited or active). DFX does not assume the company is active.

Evidence: 1 listingeach firm's own card, as read
No later owner or exit on record: no private equity sponsor position and no acquisition, listing or IPO report names this company.

Credit relationships

none on record
No lender position matched to this company.

People

0 officers, 0 directors
No officer or director on record.

Timeline

1 event
  1. Dec 16, 2025
    Allink Biotherapeutics announced Series A of $47,000,000, led by Legend Capital, Meituan Long-Z Investment
    Round announced Fact Press release

Evidence

2 observations
Every observation on this company
  • Listed on portfolio page: BRV Aster Holdings Limited Oct 1, 2026 Fact Firm website
  • Round announced: Series A $47,000,000 Dec 16, 2025 Fact Press release

Record history

1 dated event on the change ledger, latest event first
  • Round announced
    2025-12-16source on record

The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.